Home / Health / Gene Therapy Restores Sight in Children
Gene Therapy Restores Sight in Children
4 Apr
Summary
- New gene therapy uses a safer viral vector to deliver healthy genes.
- Patients regain significant vision, improving quality of life.
- FDA approval is anticipated for 2028, offering future hope.
A scientist at the University of Florida has pioneered a revolutionary gene therapy approach to treat inherited eye diseases in children. Dr. Shannon Boye's research focuses on delivering healthy gene copies to the retina using a modified adeno-associated virus (AAV) vector, dubbed AAV-SPR. This new vector is safer as it can be injected in the peripheral retina, avoiding potential damage to the fovea.
This advancement has already demonstrated remarkable results in clinical trials for conditions like X-linked retinoschisis (XLRS) and Leber congenital amaurosis type 1 (LCA1). Patients have experienced profound improvements, with one young boy describing his vision as "HDTV" after treatment, and others regaining the ability to see details like snowflakes and street signs.
Pivotal trials for these gene therapies are scheduled to commence this year. Dr. Boye's team anticipates seeking FDA approval for these sight-restoring treatments by 2028, marking a significant milestone in ophthalmology.
